AgeneBio
AgeneBio is dedicated to discovering and developing innovative therapeutics for neurological and psychiatric conditions, with a focus on delaying or preventing Alzheimer's dementia. Their pipeline includes drugs like AGB101 for MCI due to Alzheimer's, and they are engaged in clinical trials and research supported by institutions like Johns Hopkins and NIH.
Industries
Nr. of Employees
small (1-50)
AgeneBio
Carmel, Indiana, United States, North America
Patents
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-12291535-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-12024525-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-11505555-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-11414425-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-11312721-B2
View Details
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-12291535-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-12024525-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-11505555-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-11414425-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-11312721-B2
View DetailsProducts
Investigational low-dose anticonvulsant formulation for amnestic MCI (clinical-stage candidate)
An investigational therapeutic approach that uses low-dose anticonvulsant pharmacology to reduce hippocampal overactivity and improve memory in patients with amnestic mild cognitive impairment; advanced through Phase II with Phase III planning and external grant support.
Investigational low-dose anticonvulsant formulation for amnestic MCI (clinical-stage candidate)
An investigational therapeutic approach that uses low-dose anticonvulsant pharmacology to reduce hippocampal overactivity and improve memory in patients with amnestic mild cognitive impairment; advanced through Phase II with Phase III planning and external grant support.
Services
Partnership-based clinical program development with academic investigators and funding bodies to design and run neurology clinical trials using imaging and cognitive endpoints.
Early-stage discovery and preclinical activities focused on identifying and optimizing modulators selective for the GABA(A) α5 receptor as candidate therapeutics.
Partnership-based clinical program development with academic investigators and funding bodies to design and run neurology clinical trials using imaging and cognitive endpoints.
Early-stage discovery and preclinical activities focused on identifying and optimizing modulators selective for the GABA(A) α5 receptor as candidate therapeutics.
Expertise Areas
- Clinical trial management in neurology and Alzheimer’s disease
- Neuropharmacology and drug repurposing
- Translational neuroscience
- Neuroimaging biomarkers and fMRI endpoints
Key Technologies
- Task-based functional MRI (fMRI)
- Neuroimaging biomarkers of hippocampal activation
- Drug repurposing of anticonvulsant pharmacology
- Modulation of hippocampal subregions (DG/CA3)
News & Updates
AgeneBio’s Michela Gallagher and Sharon Rosenzweig-Lipson to present in Barcelona on November 7, 2015, at 11:45 am, about a clinical trial in MCI reducing hippocampal overactivity.
Johns Hopkins University researchers received a $7.5 million NIH grant to test treatment to prevent or delay dementia, in collaboration with AgeneBio.
Johns Hopkins University received an estimated $7.5 million NIH grant to test treatment to prevent or delay dementia.
A Phase 2 clinical trial of AGB101 for the pre-dementia stage of Alzheimer’s was published in NeuroImage: Clinical, supported by NIH.
Researchers at Johns Hopkins found low doses of a drug used to treat epilepsy can reverse a condition that increases the risk of Alzheimer’s.
Agenebio Inc. was issued U.S. Patent No. 8,604,075 and No. 8,510,055 covering methods and compositions for improving cognitive function and treating cognitive impairment.
AgeneBio’s Michela Gallagher and Sharon Rosenzweig-Lipson to present in Barcelona on November 7, 2015, at 11:45 am, about a clinical trial in MCI reducing hippocampal overactivity.
Johns Hopkins University researchers received a $7.5 million NIH grant to test treatment to prevent or delay dementia, in collaboration with AgeneBio.
Johns Hopkins University received an estimated $7.5 million NIH grant to test treatment to prevent or delay dementia.
A Phase 2 clinical trial of AGB101 for the pre-dementia stage of Alzheimer’s was published in NeuroImage: Clinical, supported by NIH.
Researchers at Johns Hopkins found low doses of a drug used to treat epilepsy can reverse a condition that increases the risk of Alzheimer’s.
Agenebio Inc. was issued U.S. Patent No. 8,604,075 and No. 8,510,055 covering methods and compositions for improving cognitive function and treating cognitive impairment.